https://orcid.org/0000-0002-3352-8480
References
- Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012;12(1):124. doi: 10.1186/1471-2377-12-124.
- Hellwig K, Haghikia A, Rockhoff M, et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012;5(5):247–253. doi: 10.1177/1756285612453192.
- Herbstritt S, Langer-Gould A, Rockhoff M, et al. Glatiramer acetate during early pregnancy: a prospective cohort study. Mult Scler. 2016;22(6):810–816. doi: 10.1177/1352458515623366.
- Kaplan S, Zeygarnik M, Stern T. Pregnancy, fetal, and infant outcomes following maternal exposure to glatiramer acetate during pregnancy and breastfeeding. Drug Saf. 2022;45(4):345–357. doi: 10.1007/s40264-022-01168-1.
- Sandberg-Wollheim M, Neudorfer O, Grinspan A, et al. Pregnancy outcomes from the branded glatiramer acetate pregnancy database. Int J MS Care. 2018;20(1):9–14. doi: 10.7224/1537-2073.2016-079.
- Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol. 2010;257(4):580–583. doi: 10.1007/s00415-009-5376-z.
- Lu E, Zhu F, Zhao Y, et al. Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs. CNS Drugs. 2014;28(5):475–482. doi: 10.1007/s40263-014-0154-6.
- Pecori C, Giannini M, Portaccio E, et al. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurol. 2014;14(1):114. doi: 10.1186/1471-2377-14-114.
- Miller DH, Fazekas F, Montalban X, et al. Pregnancy, sex and hormonal factors in multiple sclerosis. Mult Scler. 2014;20(5):527–536. doi: 10.1177/1352458513519840.
- Centers for Disease Control and Prevention (CDC). Metropolitan Atlanta Congenital Defects Program (MACDP). 2021 [cited 2022 Dec 20]. Available from: https://www.cdc.gov/ncbddd/birthdefects/macdp.html
- EUROCAT. European network of population-based registries for the epidemiological surveillance of congenital anomalies; [cited 2022 Nov 3]. Available from: https://eu-rd-platform.jrc.ec.europa.eu/eurocat_en
- Ventura SJ, Mosher WD, Curtin SC, et al. Highlights of trends in pregnancies and pregnancy rates by outcome: estimates for the United States, 1976-96. Natl Vital Stat Rep. 1999;47(29):1–9.
- Osterman MJK, Hamilton BE, Martin JA, et al. Births: final data for 2021. Natl Vital Stat Rep. 2023;72(1):1–53.
- Teva Pharmaceuticals Ltd. Copaxone (glatiramer acetate) 20& 40 mg/ml solution for injection in pre-filled syringe [Summary of product characteristics]. 2022 [cited 2022 Feb 10]. Available from: http://www.hpra.ie/homepage/medicines/medicines-information/find-a-medicine/results?query=Copaxone&field=
- Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018;25(2):215–237. doi: 10.1111/ene.13536.